West Pharma lifts annual forecast on strong demand
The medical supplier increased its annual profit guidance after beating first quarter estimates. Shares rose today as demand for obesity drug delivery systems grows.
WEST PHARMACEUTICAL SERVICES has significantly raised its annual profit and revenue forecasts for 2026 following a robust first-quarter performance that exceeded Wall Street expectations. The company, headquartered in the United States, is capitalizing on the surging global demand for injectable drug delivery systems, particularly those used for high-growth GLP-1 therapies.
Shares of the medical equipment manufacturer climbed nearly 13% in pre-market trading as investors reacted to the updated guidance. The company's growth is being fueled by the rapid adoption of diabetes and obesity treatments produced by major pharmaceutical players such as NOVO NORDISK A/S-B and Eli Lilly. These medications, including Ozempic and Wegovy, require specialized injection pens, plungers, and cartridges that the company specializes in producing.
